Stay updated on Avapritinib vs Regorafenib in GIST Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Regorafenib in GIST Clinical Trial page.

Latest updates to the Avapritinib vs Regorafenib in GIST Clinical Trial page
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a Phase 3 study of avapritinib (BLU-285) versus regorafenib for advanced GIST, including detailed inclusion and exclusion criteria. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference17%
- Check36 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check80 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check94 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check101 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Avapritinib vs Regorafenib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Regorafenib in GIST Clinical Trial page.